Liu Huan-Xia, He Sheng-Hua, Zhou Rui-Feng, He Yuan-Hong, Yang Tong-Tong, Yao Yuan
Infectious Disease Department One, Chengdu Public Health Clinical Medical Center, Chengdu 610061, China.
Sichuan Da Xue Xue Bao Yi Xue Ban. 2022 Sep;53(5):851-856. doi: 10.12182/20220960206.
To investigate the distribution characteristics of the HIV genetic subtypes and the status quo of transmitted drug resistance among HIV/AIDS patients in Sichuan with no previous history of receiving antiretroviral therapy (ART).
Adult HIV/AIDS patients who were hospitalized in Sichuan and who had no previous history of exposure to ART drugs exposure were enrolled. In-house sequencing of the HIV gene was done and phylogenetic tree was constructed to analyze the HIV genetic subtypes. The Stanford HIV drug resistance database was used to make online comparison of the drug resistance mutation sites and to determine the presence or absence of drug resistance, and the type and level of drug resistance.
A total of 120 patients were enrolled for the study, and 120 blood samples were collected. The genetic subtypes of 87.5% (105/120) of the samples were successfully amplified. The distribution characteristics of HIV genotype were as follows, CRF01_AE accounted for 46.67% (49/105), CRF07_BC accounted for 39.05% (41/105), and the others genetic subtypes, 14.28% (15/105). There were no significant differences between the different genetic subtypes in sex, age, ethnicity, HIV transmission route, drug resistance, baseline HIV RNA and baseline CD4 ( >0.05). Drug-resistant mutation sites were detected in 25 samples, accounting for 20.83% (25/120) of all samples, with 16.67% (20/120) being potential drug resistance and 4.17% (5/120) being transmitted drug resistance. For the 24 samples found to be resistant to non-nucleoside reverse transcriptase inhibitors (NNRTIs), the mutation frequency of V179D/E was the highest. One patient showed resistance to protease inhibitors (PI) and the mutation site was M46I. No nucleoside reverse transcriptase inhibitor (NRTI) or integrase inhibitors (INTI) resistance were found.
The main genetic subtypes of HIV/AIDS patients in Sichuan with no previous history of receiving ART were CRF01_AE and CRF07_BC. The incidence of transmitted drug resistance was low. The drug resistance detected in the study was predominantly resistance to NNRTIs. Baseline HIV drug resistance testing is of great significance for formulating effective ART regimens.
调查四川省既往无抗逆转录病毒治疗(ART)史的HIV/AIDS患者的HIV基因亚型分布特征及传播耐药现状。
纳入在四川省住院且既往无ART药物暴露史的成年HIV/AIDS患者。对HIV基因进行室内测序并构建系统发育树以分析HIV基因亚型。使用斯坦福HIV耐药数据库在线比较耐药突变位点并确定是否存在耐药以及耐药类型和水平。
共纳入120例患者进行研究,采集120份血样。87.5%(105/120)的样本成功扩增出基因亚型。HIV基因型分布特征如下,CRF01_AE占46.67%(49/105),CRF07_BC占39.05%(41/105),其他基因亚型占14.28%(15/105)。不同基因亚型在性别、年龄、民族、HIV传播途径、耐药情况、基线HIV RNA及基线CD4方面差异无统计学意义(>0.05)。25份样本检测到耐药突变位点,占所有样本的20.83%(25/120),其中潜在耐药占16.67%(20/120),传播耐药占4.17%(5/120)。在24份对非核苷类逆转录酶抑制剂(NNRTIs)耐药的样本中,V179D/E的突变频率最高。1例患者对蛋白酶抑制剂(PI)耐药,突变位点为M46I。未发现对核苷类逆转录酶抑制剂(NRTIs)或整合酶抑制剂(INTIs)耐药。
四川省既往无ART史的HIV/AIDS患者的主要基因亚型为CRF01_AE和CRF07_BC。传播耐药发生率低。本研究检测到的耐药主要为对NNRTIs耐药。基线HIV耐药检测对制定有效的ART方案具有重要意义。